Tectonic Advisors LLC Boosts Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Tectonic Advisors LLC grew its position in Zoetis Inc. (NYSE:ZTS) by 33.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,509 shares of the company’s stock after purchasing an additional 1,130 shares during the period. Tectonic Advisors LLC’s holdings in Zoetis were worth $735,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Darwin Wealth Management LLC purchased a new stake in Zoetis in the 3rd quarter valued at about $31,000. First Personal Financial Services bought a new position in shares of Zoetis in the third quarter valued at approximately $33,000. Capital Performance Advisors LLP purchased a new stake in shares of Zoetis during the third quarter valued at approximately $33,000. Dunhill Financial LLC lifted its holdings in Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares during the period. Finally, Fortitude Family Office LLC boosted its position in Zoetis by 1,387.5% in the third quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock worth $46,000 after purchasing an additional 222 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Price Performance

Zoetis stock opened at $175.65 on Thursday. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.53. The firm has a market capitalization of $79.25 billion, a P/E ratio of 33.02, a PEG ratio of 2.72 and a beta of 0.90. The business has a fifty day moving average price of $169.41 and a 200-day moving average price of $179.35.

Zoetis (NYSE:ZTS) last issued its earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter last year, the company earned $1.36 EPS. The firm’s revenue was up 11.6% compared to the same quarter last year. As a group, equities research analysts forecast that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Tuesday, January 21st. This represents a $2.00 annualized dividend and a yield of 1.14%. This is a boost from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s payout ratio is currently 37.59%.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ZTS. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Leerink Partners assumed coverage on shares of Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective for the company. JPMorgan Chase & Co. boosted their target price on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Stifel Nicolaus decreased their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Finally, UBS Group assumed coverage on shares of Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target on the stock. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $215.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.